Lexagene Resources

See how easy to use the MiQLabTM system is to detect pathogens and other molecular markers for a wide range of point-of-need applications.

MiQLab™ allows anyone on staff to screen for up to 27 pathogens and four classes of antimicrobial resistance markers from a single sample.

LexaGene’s MiQLab™ System detects up to 27 pathogens and four classes of antimicrobial resistance in ~2 hours, enabling veterinarians the ability to provide best-in-class evidence-based care for their patients.

Dr. Andrew Pierce, Owner and Medical Director of Denver Animal Emergency in North Carolina, shares his experiences with MiQLab in this testimonial video.

Listen to CEO and Founder, Dr. Jack Regan tell the LexaGene story to prospective investors, October 7, 2021.

Couldn't make it to the Lytham Partners Fall Conference this year? Here's audio of our presentation, no registration required.

Dr. Manoj Nair recently spoke at the Southwest Veterinary Symposium about applying our rapid qPCR technology in veterinary hospitals.

Learn about our fully automated system for accurate and reliable qPCR testing at point-of-care to enable evidence-based treatment decisions.

LexaGene performed a study to assess the use of the MiQLab™ Bacterial and AMR test for rapid detection of bacterial pathogens causing Urinary Tract Infections in dogs.

On Monday, June 14, Dr. Regan spoke at the Lytham Partners Summer 2021 Investor Conference about the company’s growing value as a biotechnology investment.

Download our non-confidential investor relations deck for a comprehensive investor relations and corporate update.

With the advancement of technologies such as CRISPR and CAR-T therapies, there has been a significant increase in the development and production of biologic drugs, Advanced Therapeutic Medicinal Products (ATMP) and Cell and Gene Therapies (CGT).
Next Page »